TrumpRx Cash-Pay Drug Portal Set for Launch, Targeting Direct-to-Patient Purchases

The portal is scheduled to debut Thursday evening following a brief delay last month.

The Trump administration is set to launch TrumpRx, a government-run website designed to direct patients to cash-pay options for purchasing certain prescription drugs, marking another step in President Donald Trump’s healthcare policy agenda. The portal is scheduled to debut Thursday evening following a brief delay last month.

According to the White House, Trump will unveil the platform alongside Centers for Medicare & Medicaid Services (CMS) Administrator Mehmet Oz, M.D., and National Design Studio Director Joe Gebbia. White House press secretary Karoline Leavitt said the website is intended to help Americans save money on prescription drugs.

TrumpRx was first teased in September, alongside the announcement of the administration’s “most favored nation” (MFN) drug pricing initiative, under which pharmaceutical companies are encouraged to align U.S. drug prices more closely with those paid in other developed countries. Since then, more than a dozen drugmakers have entered pricing agreements with the White House.

Pfizer was the first major pharmaceutical company to strike an MFN deal, committing to offer several of its drugs at discounted cash prices through TrumpRx.gov. At the time, Pfizer said discounts could reach up to 85%, with average savings of around 50% compared with private-sector list prices.

The TrumpRx website is expected to display cash prices for select medications using pricing technology from GoodRx, according to Stat News. The platform will not sell drugs directly; instead, it will redirect patients to third-party purchasing platforms, many of which are operated by drug manufacturers themselves. These platforms typically allow uninsured or cash-paying patients to access discounts, though prices may still exceed those paid through insurance.

The initiative follows a broader push by Trump last year urging 17 drugmakers to adopt direct-to-patient sales models and other pricing measures under the MFN framework. Of the companies named, Regeneron remains the only one yet to finalize a pricing agreement. Participation in TrumpRx has been a recurring element in those deals.

Despite the administration’s claims, questions remain over TrumpRx’s potential impact. Health policy experts have noted that the portal primarily targets cash-paying patients, limiting its relevance for the roughly 85% of Americans with prescription drug insurance coverage. Critics have also argued that pharmaceutical companies could benefit by maintaining higher list prices while offering selective discounts.

The platform was originally expected to launch in January but was delayed amid reported concerns, including potential antitrust and legal issues. Democratic Senators Dick Durbin, Peter Welch, and Elizabeth Warren have raised concerns with the HHS Office of Inspector General, warning that TrumpRx may violate federal anti-kickback laws and lacks sufficient transparency regarding oversight and compliance.

Stay tuned for more such updates on Digital Health News